How Does Hemlibra Compare With Factor VIII in Hemophilia A?

The main difference between standard factor replacement and emicizumab (Hemlibra) is how they achieve clotting and how they are administered. Traditional Factor VIII replacement involves delivering the missing clotting protein directly into a vein to either prevent or stop bleeding. In contrast, Hemlibra is a laboratory-made antibody injected just under the skin that mimics the function of Factor VIII to prevent bleeds ^[1]. While Factor VIII can be used for both prevention and rescue treatment, Hemlibra is used strictly for prevention ^[2].

At a Glance: Hemlibra vs. Factor VIII

How the Treatments Work in the Body

Normally, Factor VIII acts as a bridge in the blood, connecting two other clotting proteins—activated factor IX and factor X—to form a clot ^[1].

• Factor VIII Infusions: This treatment temporarily replaces the missing protein. However, some people develop inhibitors—immune system antibodies that recognize the infused Factor VIII as foreign, attack it, and stop it from working ^[3].
• Hemlibra (emicizumab): This medication is a bispecific antibody, meaning it is designed with two different “arms” that grab onto activated factor IX and factor X, successfully mimicking the bridging job of Factor VIII ^[4]. Because it is a completely different shape than Factor VIII, it is not targeted or neutralized by Factor VIII inhibitors ^[1]. This makes it an effective preventative treatment regardless of your inhibitor status ^[4].

Administration and Schedule

Because Hemlibra has a longer half-life (the amount of time a drug stays active in the body) than infused factor, the treatment routine is fundamentally different:

• Factor VIII: Requires frequent intravenous (IV) infusions because the body clears the protein relatively quickly. The exact schedule depends on whether you use a standard or extended-half-life product ^[5].
• Hemlibra: Is injected subcutaneously (into the fat just under the skin) ^[6]. Treatment usually begins with a weekly “loading dose” (e.g., 3 mg/kg) for the first four weeks. After that, your doctor will select a maintenance schedule of either once a week, every two weeks, or every four weeks ^[7]. Never change this schedule without your prescriber’s guidance.

In clinical studies, many participants reported a lower treatment burden and higher satisfaction when switching to Hemlibra ^[8]. However, like all medications, it has side effects; the most common are injection-site reactions (redness, itching, or pain where the shot was given) ^[9].

Treating Breakthrough Bleeds

A breakthrough bleed is any bleeding episode that occurs despite being on preventative medication. One of the most critical safety rules is that Hemlibra is strictly for prevention. It maintains a steady level of protection but cannot be given as a large rescue dose to stop an active bleed ^[2].

If you experience a breakthrough bleed, a serious injury, or “red flag” symptoms (head injury, severe headache, neck/throat swelling, abdominal pain, or uncontrolled bleeding), you must seek emergency care immediately and follow your clinic’s specific plan.

• For patients without inhibitors: Minor bleeds may sometimes be managed without extra medication, but for major bleeds or surgeries, you may need traditional Factor VIII infusions to stop the bleeding ^[2].
• For patients with inhibitors: You will likely need a bypassing agent, a medication that routes around the need for Factor VIII entirely. The preferred bypassing agent for patients on Hemlibra is recombinant activated factor VII (rFVIIa) ^[10].

Important Safety Warning about aPCC: If you have inhibitors, you must be extremely cautious with another bypassing agent called aPCC (often known by the brand name FEIBA). When high doses of aPCC are combined with Hemlibra, they can cause dangerous blood clots (thrombosis) and damage to small blood vessels (thrombotic microangiopathy) ^[9]. Medical guidelines state that aPCC doses over 100 U/kg within a 24-hour period should be avoided ^{[11] [12]}. Do not use aPCC without explicit, direct instruction from your hemophilia treatment center.

Note for transitioning patients: Do not throw away or change your supply of Factor VIII or rescue medications until your hematologist gives you a specific transition and emergency bleed plan ^[13].

Changes to Lab Testing and Emergency Protocols

Hemlibra heavily distorts standard blood clotting tests. Specifically, it makes the aPTT (activated partial thromboplastin time)—a standard test used in most hospitals to measure how quickly blood clots—look normal or short ^[14]. A normal aPTT on Hemlibra is a false reading due to test interference; it does not mean you are fully protected from bleeding ^[14].

Because routine tests are no longer reliable, your care team must use specialized tests (like chromogenic assays using specific bovine reagents) to accurately measure your clotting function or inhibitor levels ^[15].

For your safety:

• Carry a Medical ID: Always carry a Hemlibra patient alert card or medical ID jewelry.
• Inform All Providers: Tell every emergency room doctor, dentist, surgeon, and outside laboratory that you are on emicizumab and that standard aPTT tests will be inaccurate.
• Have a Written Plan: Carry a written emergency bleed plan from your hemophilia treatment center detailing exactly which rescue medications you should (and should not) receive.